BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• 

  Mergers & acquisitions

  Merck, AstraZeneca Cancer Collaborator Gets Swallowed Up by Sino Biopharm

  Shanghai-based LaNova Medicines—which has captured the attention of some of the biggest Western pharmas—will be folded into fellow Chinese company Sino Biopharmaceutical in a deal worth up to $951 million.

  July 16, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• Press Releases

  Endeavor BioMedicines Receives Orphan Drug Designation from the U.S. Food and Drug Administration and European Commission for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis

  July 16, 2025

   · 

  3 min read
• Press Releases

  IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

  July 16, 2025

   · 

  1 min read
• Press Releases

  Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

  July 16, 2025

   · 

  6 min read
• Press Releases

  Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software

  July 16, 2025

   · 

  5 min read
• Press Releases

  OmniAb to Report Second Quarter 2025 Financial Results on August 6

  July 16, 2025

   · 

  1 min read
• 

  Antibody-drug conjugate

  GSK’s Blenrep DREAMMs Turn Fitful as FDA Questions Comeback in Multiple Myeloma

  In advance of this week’s adcomm, the FDA flags ocular toxicities associated with the antibody-drug conjugate, which received accelerated approval in August 2020 but was pulled from the market two years later after a confirmatory trial failed to improve progression-free survival.

  July 16, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

  July 16, 2025

   · 

  1 min read
• 

  Earnings

  J&J Targets $50B Oncology Sales By 2030: Updated

  Johnson & Johnson’s $23.7 billion in second-quarter earnings, driven by cancer and neuroscience drugs, exceeded analyst expectations, while CEO Joaquin Duato set a target of $50 billion in oncology sales by 2030.

  July 16, 2025

   · 

  2 min read

   · 

  Nick Paul Taylor
• Press Releases

  Humanetics Corporation to Present at Upcoming Military Medical and Defense Conferences

  July 16, 2025

   · 

  3 min read